India's government is promising to vaccinate the entire adult population by the end of 2021, but questions remain over whether it will have enough doses. We've looked at what we know about production capacity in India, and other factors affecting vaccine supplies there. How much vaccine does India produce now?
(Reuters) - Bharat Biotech has terminated a memorandum of understanding to sell its COVID-19 vaccine Covaxin to Brazil's Precisa Medicamentos, the Indian company said on Friday without disclosing the reason. Bharat's statement said it will continue to work with Brazilian healthcare regulator Anvisa to obtain all required approvals for the use of Covaxin in the country.
6 fully vaccinated people who attended an outdoor wedding caught the Delta variant, but people with Pfizer and Moderna shots survived, study says
Six fully vaccinated people who attended an outdoor wedding in Texas got COVID-19, a new study says. All the breakthrough infections were in guests over 50. There were two serious cases, including one death: an attendee who'd had India's Covaxin vaccine. See more stories on Insider's business page.
Top coverage News18 Daybreak | Covaxin's Phase 3 Trial Data Looks Good, Says WHO Chief Scientist; Centre Announces Rs 23 All coverage Covaxin Closer To WHO Approval? Covid-19 Vaccine Trial Data 'Looks Good', Says Chief Scientist For you Top stories Local Following Search Clear search
JAIR BOLSONARO ran for president on a promise to end corruption in Brazil. Now he finds himself in the spotlight because of murky procurement negotiations for two covid-19 vaccines. On July 3rd thousands of Brazilians took to the streets in dozens of cities with signs bearing the names of family members they lost to the disease “for a dollar”, a reference to the sweetener-per-dose allegedly sought by one government official to purchase the AstraZeneca vaccine.
July 3 (Reuters) - Phase-III trials of a vaccine made by India's Bharat Biotech showed it was 93.4% effective against severe symptomatic COVID-19, the firm said https://www.bharatbiotech.com/images/press/barat-biotech-bbv152-covaxin-phase3-final-analysis-03July2021.pdf on Saturday, a finding that could boost people's acceptance of Covaxin. The data demonstrated 65.2% protection against the Delta variant, first identified in India, that led to a surge in infections in April and May, and the world's highest daily death tolls.
Hyderabad (Telangana) [India], July 3 (ANI): Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19. It also added that Covaxin gives 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant.
RIO DE JANEIRO, June 30 (Reuters) - Brazil's health regulator Anvisa said on Wednesday it had suspended Covaxin's emergency use application, filed by an intermediary acting on behalf of the COVID-19 vaccine developed by India's Bharat Biotech. Anvisa said the intermediary, Precisa, did not submit, or only partially submitted, mandatory and essential documents for the vaccine.
The US National Institute of Health (NIH) has found that the Indian-made vaccine, Covaxin, has the ability to 'effectively neutralise' two COVID variants of concerns—Alpha, also known as the Kent variant, and Delta, the strain originally found in India. What is Covaxin?
Washington DC [US], June 30 (ANI): The National Institute of Health (NIH) in the United States has found that Bharat Biotech's COVAXIN vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of COVID-19. The top health research institute said that an adjuvant developed with funding from the NIH has contributed to the success of the "highly efficacious" COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.
$324m deal to buy 20m doses of Indian jab has become a headache for Bolsonaro after sleaze allegations Staff and agencies Brazil will suspend a $324m Indian Covid-19 vaccine contract that has mired President Jair Bolsonaro in accusations of irregularities, health minister Marcelo Queiroga announced on Tuesday.
RIO DE JANEIRO, June 29 (Reuters) - Brazil's Health Ministry will cancel a contract for Covaxin vaccines developed by India's Bharat Biotech that has faced accusations of irregularities, CNN Brasil reported on Tuesday. The Covaxin contract has become a headache for Brazilian President Jair Bolsonaro after whistleblowers went public with concerns over irregularities in the 1.6 billion reais ($324 million) deal.
June 29 (Reuters) - India's Cipla Ltd (CIPL.NS) has received approval from the country's drugs regulator to import the COVID-19 vaccine developed by Moderna Inc (MRNA.O) for restricted emergency use, CNBC-TV18 reported on Tuesday, citing sources. Cipla had filed an application with the Drugs Controller General of India on June 28 to import the vaccine, the report said.
There was something fishy about the invoice: why was a company in Singapore billing Brazil $45 million for an Indian Covid-19 vaccine that hadn't been delivered? The request for payment for three million doses of Indian firm Bharat Biotech’s Covaxin vaccine landed on March 18 on the desk of Luis Ricardo Miranda, head of medical imports at the Brazilian health ministry.